Serum levels of antibodies against oxidised LDL in kidney graft recipients

American Journal of Nephrology

Volumn 22, Issue 5-6, 2002, Pages 539-547

  Zezina, Lilija ^a,c   Dimény, Emöke ^b   Vessby, Bengt ^a   Fellström, Bengt ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antibodies; Kidney transplantation; Lipid oxidation

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; OKT 3; OXIDIZED LOW DENSITY LIPOPROTEIN; PREDNISONE; PROTEIN ANTIBODY; THYMOCYTE ANTIBODY;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; CAUSE OF DEATH; CONTROLLED STUDY; FEMALE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIPID OXIDATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECIPIENT; SURVIVAL TIME;

ANTIBODIES; FEMALE; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; LIPOPROTEINS, LDL; MALE; OXIDATION-REDUCTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 0036977167     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000065293     Document Type: Article

References (46)

1. Vega GL, Toto RD, Grundy SM: Metabolism of low density lipoproteins in nephrotic dyslipidemia: Comparison of hypercholesterolemia alone and combined hyperlipidemia. Kidney Int 1995;47:579-586.
2. Vathsala A, Weinberg RB, Schoenberg L, Grevel J, Goldstein RA, Van-Buren CT, Lewis RM, Kahan BD: Lipid abnormalities in cyclosporine-prednisone renal transplant recipients. Transplantation 1989;48:37-43.
3. Sutherland WHF, Walker RJ, Ball MJ, Stapley SA, Robertson MC: Oxidation of low density lipoproteins from patients with renal failure or renal transplants. Kidney Int 1995;48:227-236.
4. Quaschning T, Mainka T, Nauck M, Rump LC, Wanner C, Krämer-Guth A: Immunosuppression enhances atherogenicity of lipid profile after transplantation. Kidney Int 1999; 56(suppl 71):S235-S237.
5. Fernandez-Miranda C, Morales JM, Porres A, Gomez-Gerique J, Guijarro C, Aranda JL, Andres A, Rodicio JL, Del Palacio M: Increased lipoproteins and fibrinogen in chronic renal allograft dysfunction. Am J Nephrol 1997;17:445-449.
6. Dimény E, Fellström B, Larsson E, Tufveson G, Lithell H: Chronic vascular rejection and hyperlipoproteinemia in renal transplant patients. Clin Transplant 1993;7:482-490.
7. Dimény E, Wahlberg J, Lithell H, Fellström B: Hyperlipidaemia in renal transplantation - risk factor for long-term graft outcome. Eur J Clin Invest 1995;25:574-583.
8. Kasiske BL: Risk factors for cardiovascular disease after renal transplantation. Miner Electrolyte Metab 1993;19:186-195.
9. Hammer A, Kager G, Dohr G, Rabl H, Ghas-sempur I, Jürgens G: Generation, characterization, and histochemical application of mono-clonal antibodies selectively recognizing oxidatively modified Apo-B-containing serum lipoproteins. Arterioscler Thromb Vasc Biol 1995; 15:704-713.
10. Palinski W, Hörkkö S, Miller E, Steinbrecher UP, Powell HC, Curtiss LK: Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. J Clin Invest 1996;98:800-814.
11. Nilsson J, Calara F, Rengstrom J, Hultgardh-Nilsson A, Ameli S, Cercek B, Shah PK: Immunization with homologous oxidized low density lipoprotein reduces neointimal formation after balloon injury in hypercholesterolemic rabbits. J Am Coll Cardiol 1997;30:1886-1891.
12. Palinski W, Miller E, Witztum JL: Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci USA 1995;92:821-825.
13. Fukumoto M, Shoji T, Emoto M, Kawagishi T, Okuno Y, Nishizawa Y: Anitbodies against oxidized LDL and carotid artery intima-media thickness in a healthy population. Arterioscler Thromb Vasc Biol 2000;20:703-707.
14. Salonen JT, Ylä-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R, Nyyssonen K, Palinski W, Witztum JL: Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992;339:883-886.
15. Boullier A, Hamon M, Walters-Laporte E, Martin-Nizart F, Mackereel R, Fruchart J-C, Bertrand M, Duriez P: Detection of autoantibodies against oxidized low-density lipoproteins and of IgG-bound low density lipoproteins in patients with coronary artery disease. Clin Chim Acta 1995;238:1-10.
16. Maggi E, Bellazzi R, Gazo A, Seccia M, Bello-mo G: Autoantibodies against oxidatively-modified LDL in uremic patients undergoing dialysis. Kidney Int 1994;46:869-876.
17. Van den Dorpel MA, Ghanem H, Rischen-Vos J, Man in't Veld AJ, Jansen H, Weimar W: Conversion from cyclosporine A to azatioprine treatment improves LDL oxidation in kidney transplant recipients. Kidney Int 1997;51:1608-1612.
18. Ghanem H, van den Dorpel MA, Weimar W, Man in't Veld AJ, Elkannishy MH, Jansen H: Increased low density lipoprotein oxidation in stable kidney transplant recipients. Kidney Int 1996;49:488-493.
19. Hulthe J, Wikstrand J, Lidell A, Wendelhag I, Hansson GK, Wiklund O: Antibody titers against oxidized LDL are not elevated in patients with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1998;18:1203-1211.
20. Shoji T, Nishizawa Y, Fukumoto M, Shimamura K, Kimura J, Kanda H, Emoto M, Kawagishi T, Morii H: Inverse relationship between circulating oxidized low density lipoprotein (oxLDL) and anti-oxLDL antibody levels in healthy subjects. Atherosclerosis 2000;148:171-177.
21. Dimeny E, Wahlberg J, Larsson E, Fellström B: Can histopathological findings in early renal allograft biopsies identify patients at risk for chronic vascular rejection? Clin Transplant 1995;9:79-84.
22. Wu R, Lefvert AK: Autoantibodies against oxidized low density lipoproteins (oxLDL): characterisation of antibody isotype, subclass, affinity and effect on the macrophage uptake of ox LDL. Clin Exp Immunol 1995;102:174-180.
23. Hörkkö S, Bird DA, Miller E, Reaven P, Itabe H, Leitinger N, Subbanagounder G, Berliner JA, Friedman P, Dennis EA, Palinski W, Witz-tum JL: Monoclonal antibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J Clin Invest 1999;103:117-123.
24. Keiner PA, Rankin BM, Davis PM, Yocum SA, Warr GA, Grove RI: Immune complexes of LDL induce atherogenic responses in human monocytic cells. Arterioscler Thromb Vasc Biol 1995;15:990-999.
25. Harduin P, Tailleux A, Lestavel S, Clavey V, Fruchart J-C, Fievet C: Immunological and functional properties of in vitro oxidized low density lipoprotein. J Lipid Res 1995;36:919-930.
26. Lopes-Virella MF, Koskinen S, Mironova M, Horne D, Klein R, Chassereau C, Enockson C, Virella G: The preparation of copper-oxidized LDL for the measurement of oxidized LDL antibodies by EIA. Atherosclerosis 2000;152:107-115.
27. Shaw PX, Hörkkö S, Chang M-K, Curtiss LK, Palinski W, Silverman GJ, Witztum JL: Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest 2000;105:1731-1740.
28. Tsimikas S, Shortal BP, Witztum JL: In vivo uptake of radiolabeled MDA2, an oxidation-specific monoclonal antibody, provides an accurate measure of atherosclerotic lesions rich in oxidized LDL and is highly sensitive to their regression. Atherioscler Thromb Vasc Biol 2000;26:689-697.
29. Craig WY, Poulin SE, Palomaki GE, Neveux LM, Ritchie RF, Ledue TB: Oxidation-related analytes and lipid and lipoprotein concentrations in healthy subjects. Atheroscler Thromb Vasc Biol 1995;15:733-739.
30. Ylä-Herttuala S, Palinski W, Butler SW, Picard S, Steinberg D, Witztum JL: Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Atheroscler Thromb Vasc Biol 1994;14:32-40.
31. Lehtimäki T, Lehtinen S, Solakivi T, Nikkilä M, Jaakkola O, Jokela H, Ylä-Herttuala S, Luoma JS, Koivula T, Nikkari T: Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease. Arterioscler Thromb Vasc Biol 1999;19:23-27.
32. Uusitupa MIJ, Niskanen L, Luoma J, Vilja P, Mercuri M, Rauramaa R, Ylä-Herttuala S: Autoantibodies against oxidized LDL do not predict atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 1996;16:1236-1242.
33. Craig WY, Poulin SE, Neveux LM, Palomaki GE, Dostal-Johnson DA, Ledue TB, Ritchie RF: Anti-oxidized LDL antibodies and anti-phospholipid antibodies in healthy subjects: Relationship with lipoprotein- and oxidation-related analytes. J Autoimmunity 1995;8:713-726.
34. Daschner M, Lenhartz H, Bötticher D, Schaefer F, Wollschläger M, Mehls O, Leichsenring M: Influence of dialysis on plasma lipid peroxidation products and antioxidant levels. Kidney Int 1996;50:1268-1272.
35. Roselaar SE, Nazhat NB, Winyard PG, Jones P, Cunningham J, Blake DR: Detection of oxidants in uremic plasma by electron spin resonance spectroscopy. Kidney Int 1995;48:199-206.
36. Islam KN, O'Byrne D, Devaraj S, Palmer B, Grundy SM, Jialal I: Alpha-tocopherol supplementation decreases the oxidative susceptibility of LDL in renal failure patients on dialysis therapy. Atherosclerosis 2000;150:217-224.
37. O'Byrne D, Devaraj S, Islam KN, Collazo R, McDonald L, Grundy SM, Jialal I: Low-density lipoprotein (LDL)-induced monocyte-endothelial cell adhesion, soluble cell adhesion molecules, and antibodies to oxidized-LDL in chronic renal failure patients on dialysis therapy. Metabolism 2001;50:207-215.
38. Huang YH, Ronnelid J, Frostegard J: Oxidized LDL induce enhanced antibody formation and MHC class II-dependent IFN-gamma production in lymphocytes from healthy individuals. Arterioscler Thromb Vasc Biol 1995;15:1577-1583.
39. Land W, Schneeberger H, Schleibner S, Illner WD, Abendroth D, Rutili G, Arfors KE, Messmer K: The beneficial effect of human recombinant superoxide dismutase on acute and chronic rejection events in recipients of cadaveric renal transplants. Transplantation 1994;57:211-217.
40. Hörkkö S, Miller E, Dudl E, Reaven P, Curtiss LK, Zvaifler NJ, Terkeltaub R, Pierangeli SS, Branch DW, Palinski W, Witztum JL: Anti-phospholipid antibodies are directed against epitopes of oxidized phospholipids. J Clin Invest 1996;98:815-825.
41. Amengual O, Atsumi T, Khamashta MA, Tinahones F, Hughes GRV: Autoantibodies against oxidized low-density lipoprotein in antiphospholipid syndrome. Br J Rheumatol 1997;36:964-968.
42. Ducloux D, Pellet E, Fournier V, Rebibou JM, Bresson -Vautrin C, Racadot E, Fellmann D, Chalopin JM: Prevalence and clinical significance of antiphospholipid antibodies in renal transplant recipients. Transplantation 1999; 67:90-93.
43. Wagenknecht DR, Fastenau DR, Torry RJ, Becker DG, LeFor WM, Carter CB, Haag BW, McIntyre JA: Risk of early renal allograft failure is increased for patients with antiphospholipid antibodies. Transpl Int 2000;13(suppl 1): S78-81.
44. Cristol J-P, Vela C, Maggi M-F, Decomps B, Mourad G: Oxidative stress and lipid abnormalities in renal transplant recipients with or without chronic rejection. Transplantation 1998;65:1322-1328.
45. Le N-A, Li X, Kyung S, Brown VW: Evidence for the in vivo generation of oxidatively modified epitopes in patients with atherosclerotic endothelium. Metabolism 2000;49:1271-1277.
46. Salonen JT, Ylä-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R, Nyyssonen K, Palinski W: Autoantibody against oxidized LDL and progression of carotid atherosclerosis. Lancet 1992;339:883-887.